FindTrial
Sign In

Permixon (R) 320 mg once a day open label treatment for patients participating in the placebo controlled study

Permixon (R) 320 mg once a day open label treatment for patients participating in the placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN84633360
Enrollment
Unknown
Registered
2003-09-12
Start date
2000-02-20
Completion date
Unknown
Last updated
2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia (BPH) Urological and Genital Diseases

Interventions

Permixon (R) 320 mg once a day versus placebo

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Not available.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026